Controlled release systems of angiogenic growth factors for cardiovascular diseases.
Worldwide, there is a growing number of patients with myocardial ischemia and limb ischemia associated with the aging population and an increased prevalence of atherosclerotic diseases. Medical therapy, percutaneous angioplasty and surgical revascularization are the present treatments of choice, but such treatments are not feasible for some patients with severe atherosclerosis. Therapeutic angiogenesis using growth factors or progenitor cells has drawn great attention as a favorable alternative treatment for such patients. This review discusses clinical trials using angiogenic growth factors for myocardial ischemia and limb ischemia, and also introduces a novel controlled release system for growth factors using a gelatin hydrogel.
Esaki
Jiro
J
Kyoto University Graduate School of Medicine, Department of Cardiovascular Surgery, 54 Kawara, Shogoin, Sakyo, Kyoto 606-8507, Japan.
Marui
Akira
A
Tabata
Yasuhiko
Y
Komeda
Masashi
M
D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002318:Cardiovascular Diseases / Q000628:therapy*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000628:therapy; D032383:Myocytes, Cardiac / Q000637:transplantation; D016032:Randomized Controlled Trials as Topic
D043925:Angiogenesis Inducing Agents; D003692:Delayed-Action Preparations; D036341:Intercellular Signaling Peptides and Proteins